A decrease in intact parathyroid hormone (iPTH) levels is associated with higher mortality in prevalent hemodialysis patients.

Autor: Ricardo Villa-Bellosta, Laura Rodriguez-Osorio, Sebastian Mas, Younes Abadi, Mercedes Rubert, Concepción de la Piedra, Carolina Gracia-Iguacel, Ignacio Mahillo, Alberto Ortiz, Jesús Egido, Emilio González-Parra

Publikováno v: PLoS ONE, Vol 12, Iss 3, p e0173831 (2017)

BACKGROUND:The mortality of dialysis patients is 10- to 100-fold higher than in the general population. Baseline serum PTH levels, and more recently, changes in serum PTH levels (ΔPTH) over time, have been associated to mortality in dialysis patient

Externí odkaz: https://doaj.org/article/daa11f61f33b4c6c88604467809576d4

Diferencias entre los métodos de determinación de 2.a y 3.a generación de la parathormona sérica sobre la mortalidad en el paciente en hemodiálisis

Autor: Jesús Egido, Carolina Gracia-Iguacel, Concepción de la Piedra, M. Rubert, María Luisa González Casaus, Emilio González Parra, Laura Rodriguez-Osorio, Marta Martín-Fernández, Ricardo Villa-Bellosta

Publikováno v: Nefrología (English Edition), Vol 37, Iss 4, Pp 389-396 (2017)
Nefrología (Madrid), Volume: 37, Issue: 4, Pages: 389-396, Published: AUG 2017
Biblos-e Archivo. Repositorio Institucional de la UAM
instname

Parathormone plays a key role in controlling mineral metabolism. PTH is considered a uremic toxin causing cardiovascular damage and cardiovascular mortality in dialysis patients. There are two different assays to measure PTH called 2nd generation or

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea292e1bec4dc0925fd427f6ef90c59a
http://www.sciencedirect.com/science/article/pii/S2013251417301207

Timing of eculizumab therapy for C3 glomerulonephritis

Autor: Alberto Ortiz, Laura Rodriguez-Osorio

Publikováno v: Clinical Kidney Journal

Eculizumab is an anti-C5 antibody that inhibits C5 cleavage and prevents the generation of the terminal complement complex C5b-9. Eculizumab is licensed to treat paroxysmal nocturnal haemoglobinuria or atypical haemolytic uraemic syndrome (aHUS). Cli

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::edc9bb8359a32ee14d7abe415723f196
http://europepmc.org/articles/PMC4515909

Uso del sevelamer en la enfermedad renal crónica. Más allá del control del fósforo

Autor: Alberto Ortiz, Emilio González Parra, Carolina Gracia-Iguacel, Laura Rodriguez-Osorio, Jesús Egido, Diana Pazmiño Zambrano, Jorge Rojas-Rivera

Publikováno v: Nefrología, Vol 35, Iss 2, Pp 207-217 (2015)
Nefrología (Madrid) v.35 n.2 2015
SciELO España. Revistas Científicas Españolas de Ciencias de la Salud
instname

ResumenEl sevelamer es un captor no cálcico de fósforo que se utiliza en la ERC avanzada y en diálisis para el control de la hiperfosforemia. Varios estudios experimentales, observacionales y ensayos clínicos han mostrado que el sevelamer tiene e

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4987038c3d653b018e2e876f5c171c64
http://www.sciencedirect.com/science/article/pii/S0211699515000363

Correction of hypocalcemia allows optimal recruitment of FGF-23-dependent phosphaturic mechanisms in acute hyperphosphatemia post-phosphate enema

Autor: Laura Rodriguez-Osorio, Emilio González-Parra, Carolina Gracia-Iguacel, Mariano Rodriguez, Jesús Egido, Concepción de la Piedra, Yolanda Almaden, Alberto Ortiz, Ana Belen Sanz

Publikováno v: Journal of Bone and Mineral Metabolism. 31:703-707

Both parathyroid hormone (PTH) and fibroblast growth factor 23 (FGF23) are phosphaturic hormones. These hormones should increase in response to phosphate excess. However, they also regulate serum calcium; PTH increases serum calcium concentration and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::22a4918f26e304a231c7620842de02df
https://doi.org/10.1007/s00774-013-0435-z